Skip to content

Normative Assessment of Adaptable Mouthguards.

Normative Assessment of Adaptable Mouthguards.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04056559
Acronym
ENORMPIBA
Enrollment
14
Registered
2019-08-14
Start date
2011-09-09
Completion date
2012-06-29
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Manifestations

Keywords

Prototype, Adaptable mouthguards

Brief summary

The aim of this study is to the validate adaptable mouthguards prototypes, patented by Bordeaux University and Bordeaux University Hospital.

Detailed description

The current state of knowledge in the areas of mouthguards shows that type II (adaptable) models account for 90% of the mouthguards of the sporting population. But a majority of these devices do not appear to comply with the European Directive 89/686 / European Economic Community. A previous work consisted of the production of prototypes of mouthguards meeting the essential requirements of the directive. These prototypes were the subject of a patent filed by the Bordeaux University and the Bordeaux University Hospital. The aim of this study is to the validate the prototypes for a future launch on the market.

Interventions

DEVICEAdaptable mouthguards

Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

Single

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject aged 18 to 35, * Subject affiliated to a social security, * Subject who has signed the free and informed consent form.

Exclusion criteria

* Subject with a pathology incompatible with the performance of the test, namely: Recent infarction,Threat syndrome, blood pressure resting\> 200/120 mmHg, uncompensated cardiac insufficiency, atrioventricular block 3rd degree acquired, Myocarditis, Pericarditis, Endocarditis, Aortic Dissection, Intracardiac Tumor or Thrombus, Deep Vein Thrombosis, Pulmonary Embolism, * Subject under B-mimetic drug treatment, * Subject under safeguard of justice, * Subject participating in another search, * Subject during pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Impact on ventilatory flow rate by minuteAt Week 51Average of measured values in one minute, compared to maximum aerobic reference speed of the subject Modification of the ventilatory flow rate by min
Impact on O2 consumptionAt Week 51Average of measured values in one minute, compared to reference of the subject
Impact on respiratory rateAt Week 51Average of measured values in one minute, compared to reference of the subject
Impact on current volumeAt Week 51Average of measured values in one minute, compared to reference of the subject
Impact on CO2 productionAt Week 51Average of measured values in one minute, compared to reference of the subject
Impact on comfort according an analogical visual scale for 11 criteriaAt Week 51According an analogical visual scale (from 0 to 10) for 11 criteria (retention, muco-gingival appearance, mouth opening height, volume of mouthguards, nausea, phonation, open mouth ventilation, tight jaw ventilation, salivation, masticatory muscles, temporomandibular joint)
Impact on electromyographic recordingAt Week 52The electromyographic activity will be amplified and filtered (bandwidth 10-1000 Hz). The signals will be digitized using a CED 1401 interface coupled to a microcomputer that is controlled by the "SPIKE2" software. The digitization frequency will be 2,000 Hz. The software "SPIKE2" will then calculate what is called "integrated electromyogram": the electromyographic signals will be rectified and filtered with a moving average having a period of 0,2 seconds.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPhilippe POISSON, Dr

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026